Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study - PubMed (original) (raw)
Comparative Study
doi: 10.1046/j.1365-2559.2003.01598.x.
G MacGrogan, J Couturier, L Arnould, Y Denoux, M Fiche, J Jacquemier, M-C Mathieu, F Penault-Llorca, C Rigaud, P Roger, I Treilleux, M-O Vilain, S Mathoulin-Pélissier, V Le Doussal
Affiliations
- PMID: 12653945
- DOI: 10.1046/j.1365-2559.2003.01598.x
Comparative Study
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study
A Vincent-Salomon et al. Histopathology. 2003 Apr.
Abstract
Aims: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a common and inexpensive method able to specifically detect HER2 protein. However, lack of standardization of IHC has been considered responsible for discrepancies in HER2 status assessment performed by IHC and fluorescence in-situ hybridization (FISH). This prompted us to perform a multicentric IHC calibration test to achieve a maximum accuracy of HER2-IHC compared with HER2-FISH taken as the reference method.
Methods and results: Twelve French laboratories participated in this study, including 119 cases of invasive breast carcinomas for which both fixed and frozen tissues were available. HER2 expression was determined in fixed tissues by individual in-house IHC techniques, using either CB11 (Novocastra, Newcastle, UK) or A0485 (Dako, Glostrup, Denmark) anti-HER2 antibodies. Two cut-off values were used: 10% and 60% of immunostained cells. In 116 of the 119 cases, HER2 gene status could also be determined by FISH on frozen sections, performed in a single laboratory. Results were centralized and compared. When suboptimal concordance between IHC and FISH was observed, IHC was calibrated and a second run was performed. The specificity, sensitivity and accuracy of IHC compared with FISH were noted before and after calibration. Forty-four out of 116 (38%) tumours showed HER2 gene amplification. Accuracy of IHC was complete in the first run for 6/12 laboratories. Calibration, necessary for the six others, relied mainly on the combination of a heat-induced epitope retrieval step with an increase of dilution of the primary antibody. In the second run, HER2 over-expression was found in 46 (40%) and 44 (38%) of the 116 cases, using 10% or 60% of stained cells as cut-offs, respectively. The corresponding accuracy rates were 93% and 95%.
Conclusions: This study showed that a high accuracy of IHC could be obtained for the determination of HER2 status in all laboratories using their in-house IHC technique, provided that a calibration process was performed. Antigen retrieval procedure, high dilutions of anti-HER2 antibody and the use of specific controls were crucial for HER2-IHC calibration. A 95% accuracy rate of IHC, using FISH as gold standard, was obtained by considering immunolabelling HER2-IHC results as a continuous variable, and taking 60% invasive stained cells as the cut-off for HER2 over-expression.
Similar articles
- Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
Bánkfalvi A, Simon R, Brandt B, Bürger H, Vollmer I, Dockhorn-Dworniczak B, Lellé RJ, Boecker W. Bánkfalvi A, et al. Histopathology. 2000 Nov;37(5):411-9. doi: 10.1046/j.1365-2559.2000.00984.x. Histopathology. 2000. PMID: 11119122 - HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
Kovács A, Stenman G. Kovács A, et al. Pathol Res Pract. 2010 Jan 15;206(1):39-42. doi: 10.1016/j.prp.2009.08.003. Epub 2009 Oct 12. Pathol Res Pract. 2010. PMID: 19819642 - A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer.
Wesoła M, Jeleń M. Wesoła M, et al. Adv Clin Exp Med. 2015 Sep-Oct;24(5):899-903. doi: 10.17219/acem/27923. Adv Clin Exp Med. 2015. PMID: 26768643 Review. - Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study.
Memon R, Prieto Granada CN, Harada S, Winokur T, Reddy V, Kahn AG, Siegal GP, Wei S. Memon R, et al. Clin Breast Cancer. 2022 Jan;22(1):e123-e133. doi: 10.1016/j.clbc.2021.05.004. Epub 2021 May 17. Clin Breast Cancer. 2022. PMID: 34120846 Review.
Cited by
- Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, Loening T, Pantel K. Riethdorf S, et al. J Cancer Res Clin Oncol. 2011 Feb;137(2):261-9. doi: 10.1007/s00432-010-0881-0. Epub 2010 Apr 16. J Cancer Res Clin Oncol. 2011. PMID: 20396915 - RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.
Delfour C, Roger P, Bret C, Berthe ML, Rochaix P, Kalfa N, Raynaud P, Bibeau F, Maudelonde T, Boulle N. Delfour C, et al. J Mol Diagn. 2006 May;8(2):157-69. doi: 10.2353/jmoldx.2006.050105. J Mol Diagn. 2006. PMID: 16645201 Free PMC article. - Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, Lassen U, Vassal G, Sullivan SD. Stenzinger A, et al. Oncologist. 2023 May 8;28(5):e242-e253. doi: 10.1093/oncolo/oyad005. Oncologist. 2023. PMID: 36961477 Free PMC article. - A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.
Kwon S, Cho CH, Kwon Y, Lee ES, Park JK. Kwon S, et al. Sci Rep. 2017 Apr 5;7:45968. doi: 10.1038/srep45968. Sci Rep. 2017. PMID: 28378835 Free PMC article. - SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F. Jacquemier J, et al. BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351. BMC Cancer. 2013. PMID: 23875536 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous